GLP-1 Weight Loss Drugs Linked to 17% Fewer Long-Term Sick Days

GLP-1 medications are transforming obesity and diabetes care, with emerging evidence of benefits for health outcomes and daily functioning.

GLP-1 weight loss drugs may be delivering benefits beyond obesity and diabetes treatment. Researchers analyzing linked Danish health and employment records found that adults who initiated Ozempic treatment experienced a 17.3% reduction in medically certified long-term sickness leave over four years.
The study also reported fewer emergency department visits, lower use of cardiovascular medications, and measurable economic benefits, highlighting how better management of chronic diseases may influence everyday life and healthcare costs (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source

).

Obesity affects more than 1 billion people worldwide and remains one of the leading contributors to chronic illness globally (3^✔ ✔Trusted Source
Obesity and overweight

Go to source). Conditions such as obesity and type 2 diabetes can influence energy levels, mobility, mental well-being, and quality of life. As treatments improve, researchers are increasingly exploring whether their benefits extend beyond traditional health outcomes.

The researchers used a matched sample of 7,011 early Ozempic initiators and 7,011 comparable patients who began treatment approximately four years later. Using linked nationwide administrative data and a matched stacked difference-in-differences design, they examined how GLP-1 treatment influenced long-term health and labor market outcomes over four years (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source).

GLP-1 Study Finds 17.3% Reduction in Long-Term Sick Leave

Researchers focused on medically certified sickness absence lasting longer than 30 days and found that long-term sickness leave declined progressively over time (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source

).

The reduction was approximately 0.8 percentage points during the first two years and increased to 1.1 percentage points during years three and four (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source).

Supplementary analyses also suggested a decline in all sickness absences, including shorter absences lasting fewer than 30 days. In these analyses, the relative reduction was estimated at approximately 8.7% (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source).

Importantly, the study found no significant effects on employment rates, labor force participation, or total income over the four-year follow-up period (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source).

How Ozempic Treatment Was Linked to Better Health Outcomes

GLP-1 receptor agonists are medicines that mimic a natural hormone called glucagon-like peptide-1. This hormone helps regulate appetite, slows stomach emptying, and improves blood sugar control (2^✔ ✔Trusted Source
Introduction and Methodology

Go to source

).

Common GLP-1 medications include Ozempic (semaglutide), Wegovy (semaglutide), liraglutide, and dulaglutide. These medicines are prescribed under medical supervision for approved conditions such as obesity and type 2 diabetes (2^✔ ✔Trusted Source
Introduction and Methodology

Go to source).

Researchers also observed fewer emergency department visits and lower use of cardiovascular medications among people receiving GLP-1 treatment, findings that are consistent with gradual improvements in underlying health (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source).

Can GLP-1 Drugs Reduce Healthcare Costs and Economic Burden?

The study estimated that reduced prolonged sickness absence translated into economic benefits equivalent to approximately 1.3% to 1.5% of annual labor income per employed individual receiving treatment (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source

).

However, the authors cautioned that these fiscal benefits remain substantially smaller than the current cost of GLP-1 therapies in 2026 (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source).

Researchers further estimated that approximately 55% of the savings associated with reduced sickness absence would accrue to employers, while the remaining benefits would be shared across public systems responsible for sickness payments (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source).

These findings contribute to ongoing discussions about GLP-1 coverage and reimbursement policies in several countries.

Key Findings from the Danish GLP-1 Study

What Are the Limitations of This GLP-1 Research?

This study has several important limitations.

First, it was observational and cannot establish cause and effect (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source). Second, the findings are currently available as a working paper and have not yet undergone peer review.

The authors emphasized that early Danish Ozempic users were likely patients with a clear medical need. Therefore, the findings should not be generalized to people seeking GLP-1 medications primarily for cosmetic weight loss or to populations in countries with different healthcare systems (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source).

In addition, Denmark’s healthcare and sickness benefit systems differ substantially from those in countries such as India and the United States, which may affect how these findings translate internationally.

Why This GLP-1 Study Matters Beyond Weight Loss

For millions of people living with obesity and type 2 diabetes, treatment is about much more than losing weight. It is about having more energy, avoiding complications, and participating fully in work, family life, and everyday activities.

While the study does not suggest that GLP-1 medicines are a solution for workplace absenteeism, it reinforces a broader message: effective treatment of chronic diseases can have ripple effects that extend beyond the clinic. For patients with obesity and type 2 diabetes, better health may mean fewer complications, fewer hospital visits, and more time spent participating in everyday life.

As researchers continue to study GLP-1 therapies, their impact may prove to be measured not only in kilograms lost, but also in improvements to long-term health and well-being (1^✔ ✔Trusted Source
The Labor Market Impacts of GLP-1s

Go to source).

References:

1. The Labor Market Impacts of GLP-1s – (https://meltemdaysal.com/docs/glp1-labor.pdf)
2. Introduction and Methodology
   – (https://diabetesjournals.org/care/issue/49/Supplement_1)
3. Obesity and overweight
   – (https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)

Source-Medindia